CLOs on the Move

Global Blood Therapeutics

www.gbt.com

 
GBT is a clinical-stage biopharmaceutical company determined to discover, develop and deliver innovative treatments that provide hope to underserved patient communities. GBT is developing its late-stage product candidate, voxelotor (previously called GBT440), for the treatment of sickle cell disease.
  • Number of Employees: 100-250
  • Annual Revenue: $0-1 Million
  • www.gbt.com
  • 171 Oyster Point Boulevard Suite 300
    South San Francisco, CA USA 94080
  • Phone: 650.741.7700

Executives

Name Title Contact Details
Ernie Hernandez
Vice President and Chief Compliance Officer Profile

Similar Companies

Endobiologics

Endobiologics is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

NewLeaf Symbiotics

NewLeaf Symbiotics® is at the forefront of sustainable agriculture technology, with a singular focus on the identification, development and commercialization of the beneficial microbes called pink pigmented facultative methylotrophs (M-trophs). This new class of agricultural microbes is helping transition agricultural products and production to deliver better quality crops, with less impact on the environment — a win-win for growers and those of us who depend on their success.

Institute for Protein Design

We aim to design a new world of proteins to address 21st century challenges in medicine, energy, and technology.

Omnicare Distribution Center

Omnicare Distribution Center is a Toledo, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Castle Biosciences

Castle Biosciences, Inc. specializes in diagnostic tests for cancers. Founded in 2008, the company goal has been to help advance the care for cancers through objective testing. Our team works with outstanding members of the oncology community throughout the discovery, development and utilization of these tests. Currently, Castle Biosciences has tests to help doctors treat glioblastoma, uveal melanoma, low grade gliomas. We anticipate tests for thymoma and esophageal cancer to be on the market in the near future (1Q-1H, 2012) as they are going through final validation.